Point72 (Difc) LTD C4 Therapeutics, Inc. Transaction History
Point72 (Difc) LTD
- $1.53 Trillion
- Q3 2025
A detailed history of Point72 (Difc) LTD transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Point72 (Difc) LTD holds 234 shares of CCCC stock, worth $577. This represents 0.0% of its overall portfolio holdings.
Number of Shares
234
Previous 3,953
94.08%
Holding current value
$577
Previous $5.65 Million
90.82%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CCCC
# of Institutions
109Shares Held
55.4MCall Options Held
329KPut Options Held
186K-
Lynx1 Capital Management LP San Juan, PR7.1MShares$17.5 Million3.06% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.05MShares$17.4 Million0.95% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.24MShares$12.9 Million0.4% of portfolio
-
Morgan Stanley New York, NY4.97MShares$12.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$12 Million0.06% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $121M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...